Patent on Adaptivex™ Primer for Dengue Virus

Share Article

Co-Diagnostics’ newly-patented technology allows the primer of a polymerase chain reaction (PCR) test to skip over mutations in the genetic code, detecting the presence of the virus that other tests can miss (false negatives).

Co-Diagnostics, Inc. announced today that on Friday, March 28, the company received patent approval for Patent No. US 8,673,569 B2, titled “Primers for Nucleic Acid Extension or Amplification Reactions.” This patent relates to Co-Diagnostics’ Adaptivex Primer™ technology as applied to detecting the Dengue virus.

Dengue virus is a leading cause of hemorrhagic fever in many parts of the world. Mutations in the genetic sequence of the virus make it hard to detect in clinical diagnostics. This newly-patented technology works by allowing the primer in the polymerase chain reaction to skip over mutations in the genetic code, detecting the presence of the virus when other tests would not, causing a false negative.

According to the Centers for Disease Control and Prevention (CDC), “With more than one-third of the world’s population living in areas at risk for infection, dengue virus is a leading cause of illness and death in the tropics and subtropics. As many as 400 million people are infected yearly…When infected, early recognition and prompt supportive treatment can substantially lower the risk of medical complications and death.”

Co-Diagnostics CEO Dwight Egan noted, “Using the Adaptivex Primer technology will both decrease false negatives and increase sensitivity of tests that are of vital importance in tropical regions, where access to real-time, accurate diagnoses can mean the difference between life and death. Adaptivex Primers fit perfectly with the Co-Diagnostics business model of designing life-saving testing platforms for which there is currently high demand. We can now proceed to license this technology, confident that it has the full protection of the United States Patent Office.”

About Co-Diagnostics
Co-Diagnostics, Inc., a molecular diagnostics company, is a Utah corporation based in Sandy, Utah that develops, manufactures and markets fully integrated DNA test systems. The company’s intellectual property is based on mathematical principles that create algorithms in a unique DNA-based diagnostics system that is superior in cost and speed of development to all other such systems, both in the US and abroad.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Dwight Egan
Visit website